AstraZeneca prevails in GSK royalties row at UK High Court

Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Effects of GSK v Teva ripple after SCOTUS denies cert

23 May 2023 Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.

Big Pharma

AstraZeneca sues Taro in blood-thinning drug patent dispute

24 February 2022 AstraZeneca has sued Taro Pharmaceuticals in two US federal courts alleging that Taro’s planned generic blood-thinning treatment infringes a patent for its Brilinta (ticagrelor) medication.

Americas

AstraZeneca prevails in inhaler dispute

9 March 2021 AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.